Why Investors Should Take Another Look At Alnylam Pharmaceuticals
October 24, 2016 at 15:31 PM EDT
Piper Jaffray reiterated its Overweight rating and $106 target price on Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) despite ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.